Evidence mapPaperPMID 41804200Full record

ArticleDiabetes, obesity & metabolism2026

Demographic Change in Prevalent Type 1 Diabetes Adult Population, and Association of Risk Factors With Comorbidities and Mortality-Results From the Finnish Diabetes Control Study FinDiCon.

Hannu Vessari, Tuire Prami, Essi J Peltonen, Elina Pimiä, Ilona Iso-Mustajärvi, Marita Kalaoja, Hanne Luoto, Ilkka Vauhkonen, Tero Saukkonen

Abstract read
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hannu VessariNovo Nordisk, Espoo, Finland.ORCID https://orcid.org/0009-0001-7367-4773
Tuire PramiOriola, Espoo, Finland.ORCID https://orcid.org/0000-0001-8672-9465
Essi J PeltonenOriola, Espoo, Finland.ORCID https://orcid.org/0000-0002-5782-3089
Elina PimiäFinnish Diabetes Association, Tampere, Finland.ORCID https://orcid.org/0000-0002-4453-689X
Ilona Iso-MustajärviOriola, Espoo, Finland.ORCID https://orcid.org/0009-0008-7429-3279
Marita KalaojaOriola, Espoo, Finland.ORCID https://orcid.org/0000-0002-0755-7296
Hanne LuotoNovo Nordisk, Espoo, Finland.
Ilkka VauhkonenNovo Nordisk, Espoo, Finland.ORCID https://orcid.org/0009-0001-6785-0515
Tero SaukkonenNovo Nordisk, Espoo, Finland.ORCID https://orcid.org/0009-0003-5133-721X

Funding

Novo Nordisk
6 · The paper itself

Abstract

aimsThe objective was to characterise Finnish adults with type 1 diabetes (T1D) and to explore associations between known risk factors, comorbidities and mortality. MATERIALS AND

methodsIndividuals with T1D in 2014-2021 were identified from national health care registers, and data on medication and comorbidities were combined with laboratory measurements from hospital data lakes. Comorbidity and risk-factor associations were examined using Cox regression.

resultsWe identified 35 574 adults with T1D. The proportion of individuals aged over 70 years increased during the study period from 7.1% to 12.4% and the proportion of insulin pump users from 10% to 17%. Mean haemoglobin A1c (HbA1c) decreased by 1.7 mmol/mol (0.2%) and mean low-density lipoprotein cholesterol (LDL-c) by 0.2 mmol/L (7.7 mg/dL) from 2014 to 2021. The proportion of individuals with HbA1c > 75 mmol/mol (> 9.0%) reduced slightly (4%-points); this improvement was more prominent in insulin pump users (9%-points). Ketoacidosis was most common in young adults. Prevalence of chronic kidney disease (CKD) increased from 140 (95% CI 136-145) to 168 (95% CI 163-172) per 1000 persons during the study period (p-trend < 0.001). CKD and vascular disease resulted in a multifold increase in the mortality risk, whereas lipid-lowering and antihypertensive medications reduced this risk (p < 0.001 for all).

conclusionsThe proportion of elderly with T1D is increasing, with no concomitant increase in vascular events. Insulin pump therapy has become more common without a concomitant increase in ketoacidosis incidence. HbA1c and LDL-c levels improved during the study. Finnish data indicate a shift in T1D demographics, characterised by improved survival, while rates of diabetes-specific comorbidities remain stable.

Indexed as

Diabetes Mellitus, Type 1AdultAgedComorbidityFemaleFinlandGlycated HemoglobinHumansInsulin Infusion SystemsMaleMiddle AgedPrevalenceRisk FactorsYoung AdultGlycated Hemoglobincohort studyinsulin pump therapyinsulin therapytype 1 diabetes

Identifiers

PMID41804200
PMCPMC13146149

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.